The association between pembrolizumab and risk of venous thromboembolism in patients with breast cancer

Thromb Res. 2024 Oct:242:109119. doi: 10.1016/j.thromres.2024.109119. Epub 2024 Aug 17.

¹ Department of Medicine, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, USA. Electronic address: [email protected].
² Division of Hematology and Oncology, Department of Medicine, University of Vermont Medical Center, Burlington, VT, USA.
³ Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
⁴ Department of Medicine, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, USA.
⁵ Department of Medicine, Danbury Hospital, Danbury, CT, USA.
⁶ Section of Neurosurgery, Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
⁷ School of International and Public Affairs, Columbia University, New York, NY, USA.
⁸ Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
⁹ Department of Oncology, Montefiore Einstein Comprehensive Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.

No abstract available

Keywords: Breast cancer; Deep venous thrombosis; Immune checkpoint inhibitor; Pembrolizumab; Pulmonary embolism; Venous thromboembolism.

Publication types